Back to Journals » OncoTargets and Therapy » Volume 7

Comprehensive clinical and pathological analysis of aggressive renal epithelioid angiomyolipoma: report of three cases

Authors Luo J, Liu B, Wang Y, Li J, Wang P, Chen J, Wang C

Received 29 January 2014

Accepted for publication 17 March 2014

Published 27 May 2014 Volume 2014:7 Pages 823—827

DOI https://doi.org/10.2147/OTT.S61524

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Jindan Luo,1 Ben Liu,1 Yanli Wang,2 Jun Li,2 Ping Wang,1 Jun Chen,1 Chaojun Wang1

1Department of Urology, 2Department of Pathology, The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, People's Republic of China

Abstract: Renal angiomyolipoma (AML) is recognized as a benign hamartomatous lesion arising in the kidney with no obvious malignant potential. However, epithelioid AML (EAML), a rare variant of AML, is potentially malignant, with aggressive clinical features. It can occur in patients with or without tuberous sclerosis. Because EAML may mimic renal cell carcinoma in imaging studies, differentiation of this tumor from renal cell carcinoma preoperatively is difficult. At times, the lesions may extend into the renal vein and inferior vena cava or metastasize to other organs such as the lung and liver. To clarify the biological nature of EAML, three specific cases that we encountered in clinical practice are analyzed and reported in detail.

Keywords: kidney, malignant, inferior vena cava


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]